Telavant: Roche's $7.1 Billion Acquisition of Telavant
Davis Polk & Wardwell is advising Roche on the transaction, and Freshfields Bruckhaus Deringer is advising Roivant. Roivant (Nasdaq: ROIV) announced it has entered into a definitive [...]
Read full article »
Telavant is a New York-based biotechnology company that researches and develops novel therapeutics for the treatment of inflammatory and fibrotic diseases.
Read more